Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF Challenge Study
NCT03334695Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Oct 2017; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03334695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334695.